Health
India Fat-Loss Drug Sales Slow After Early Spike From Generics
Key Points
India Fat-Loss Drug Sales Slow After Early Spike From Generics Growth in India’s obesity- and diabetes-drug market is losing steam just months after a surge triggered by the arrival of generic semaglutide products. Monthly sales of GLP-1 drugs rose just 2.3% in June, data from market research firm Pharmarack showed. That’s down from 12.1% growth in May and 58.4% in April.
India Fat-Loss Drug Sales Slow After Early Spike From Generics
Growth in India’s obesity- and diabetes-drug market is losing steam just months after a surge triggered by the arrival of generic semaglutide products.
Monthly sales of GLP-1 drugs rose just 2.3% in June, data from market research firm Pharmarack showed. That’s down from 12.1% growth in May and 58.4% in April.